Novel Tool Enables High-Precision, Low-Cost Pediatric Leukemia Diagnostics

Researchers have introduced a novel diagnostics method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available fusion detection algorithms. The tool, detailed in an articleopens in new tab/window appearing in The Journal of Molecular Diagnosticsopens in new tab/window, published by Elsevier, enables a higher diagnostic yield from low-coverage, low-cost sequencing.

Current treatment of B-ALL is classified according to risk levels depending on age, white blood cell count, response to therapy, central nervous system status, and genomic subtype. Pediatric B-ALL is primarily driven by chromosomal abnormalities or structural variants, which typically result in fusion oncogenes that cause cancer cells to grow and multiply. It is critical to diagnose B-ALL genomic subtypes for appropriate risk-stratified treatment.

The novel algorithm, called FUSILLI (FUSions In Leukemia for Long-read sequencing Investigator), has been developed to detect these fusion genes. It uses Oxford Nanopore Technologies’ (ONT) long-read sequencing, which looks at larger DNA and RNA fragments and is easier to implement across various resource contexts compared to short-read sequencing technology.

The researchers working on this new tool have previously demonstrated the use of nanopore RNA sequencing to classify B-ALL. Now, the sensitive and accurate method for detecting gene fusion subtypes presented in FUSILLI closes a critical gap in using these data for clinical fusion detection.

“Long-read sequencing, and nanopore sequencing specifically, represent a new era of sequencing compared to more conventional short-read sequencing approaches. It has been around for about a decade but is now becoming mature enough for clinical applications,“ notes senior investigator Jeremy R. Wang, PhD, Department of Genetics, Department of Pathology and Laboratory Medicine, and Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill.

“Compared to traditional short-read next-generation sequencing, nanopore sequencing has dramatically lower capital and consumables costs and much faster turnaround time, making it particularly advantageous in resource-limited diagnostic settings. Our research builds on this technology to show the potential of diagnosing genomic subtypes of pediatric cancers, which are traditionally resolved through several different expertise- and resource-intensive assays.”

The investigators took a supervised approach at what filtering parameters were needed to detect true B-ALL gene fusions as compared to results obtained from clinical testing. For gene fusion detection, there can be false positives that result from both technical and computational artifacts.

“From our experience, we’ve seen sequencing chimeras (artificial DNA sequences created during the sequencing process), producing long reads that resemble true gene fusions. These are rare events. With careful filtering and sufficient sequencing depth, we discriminate these from true B-ALL gene fusions supported by a minimum of two reads,” explains Dr. Wang.

The study further established a limit of detection, finding that approximately 10 million reads per sample are required to reliably detect B-ALL fusions using this approach.

Additionally, researchers compared results against other publicly available fusions callers (with default parameters) and demonstrated superior sensitivity without significant loss of specificity for clinically relevant fusion events. Also, because they limited the data to clinically relevant B-ALL gene fusions, the researchers achieved a much smaller search space and faster computation times.

While the primary leukemic-driving fusions are the dominant fusion detected in most cases, the team observed an unexpected number of suggestive secondary alterations in the cohorts’ data. “For instance, we see PAX5::ZCCHC7 in several cases, which is a known secondary alteration, but less is known about its clinical relevance. A better understanding of these lesser-known genomic events that are not well captured by existing diagnostic tools has the potential to further improve risk stratification and personalized medicine.”

Dr. Wang concludes, “With the development of FUSILLI, we show the potential of using a single low-cost sequencing assay for diagnosing gene fusion subtypes of B-ALL, with faster turnaround time. Modern genomic subtyping in pediatric B-ALL informs risk-stratification and targeted therapy, improving treatment response rate and reducing unnecessary treatment-related toxicity.”

Notes for editors

The article is “Long-Read Whole-Transcriptome Sequencing and Selective Gene Panel Profiling Enable Sensitive Detection of Fusion Oncogenes in Pediatric B-Cell Acute Lymphoblastic Leukemia,” by John Lin, Kofi B. Opoku, Mark R. Litzow, Elisabeth Paietta, Ching-Hon Pui, Sima Jeha, Kathryn G. Roberts, Charles G. Mullighan, Thomas B. Alexander, and Jeremy R. Wang (https://doi.org/10.1016/j.jmoldx.2026.01.007opens in new tab/window). The article appears in volume 28, issue 5 (May 2026) of The Journal of Molecular Diagnostics, published by Elsevier.

The article is openly available at https://www.jmdjournal.org/article/S1525-1578(26)00021-8/fulltextopens in new tab/window.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window to request a PDF of the article or additional information. To reach the study’s authors contact Lindsey Reich, Communications Specialist, UNC School of Medicine/UNC Health, Department(s) of Orthopaedics and Pathology and Laboratory Medicine, at [email protected]opens in new tab/window.

This study was supported by the National Cancer Institute of the NIH under award numbers R01CA293366, R21CA259926, U10CA180820, UG1CA232760, and UG1CA189859; and National Institute of General Medical Sciences predoctoral training grant T32GM135123. Institutional and biobanking support was provided by UNC Lineberger Comprehensive Cancer Center, the University Cancer Research Fund, Hyundai Hope on Wheels, and Reelin’ for Research.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnosticsopens in new tab/window, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.orgopens in new tab/window

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야의 글로벌 선도 기업으로 100년 넘게 과학과 헬스케어의 발전을 지원하며 인류 진보에 기여해 왔습니다. 우리는 170개국 이상에서 학술 및 기업 연구 커뮤니티, 의사, 간호사, 미래의 의료 전문가와 교육자들을 지원합니다. 근거에 기반한 신뢰할 수 있는 과학·의학 콘텐츠와 최첨단 AI 기술을 결합해 중요한 통찰과 혁신적인 솔루션을 제공해, 의미있는 성과를 이루도록 돕고 있습니다. 또한 다양성과 지속 가능성을 제품과 기업 문화 전반에 내재화하며, 우리가 속한 커뮤니티와 협력합니다. 엘스비어 재단opens in new tab/window은 전 세계에서 연구와 보건 파트너십을 지원합니다.

엘스비어는 전문가 및 기업 고객에게 정보 기반의 분석과 의사결정 도구를 제공하는 글로벌 기업 RELXopens in new tab/window의 일원입니다. 자세한 내용은 www.elsevier.com에서 확인할 수 있으며, 소셜미디어 @elsevierconnect를 통해 최신 소식을 받아보실 수 있습니다.